Legal & General Group
SGMO

Legal & General Group’s SANGAMO THERAPEUTICS INC SGMO Stock Holding History

Legal & General Group’s Portfolio SGMO Stock Details SGMO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-13,096
Closed -$8.76K – 3498
2024
Q1 		$8.76K Hold
13,096
– – ﹤0.01% 3229
2023
Q4 		$7.12K Hold
13,096
– – ﹤0.01% 3278
2023
Q3 		$7.86K Hold
13,096
– – ﹤0.01% 3310
2023
Q2 		$17K Sell
13,096
-17,917
-58% -$24.5K ﹤0.01% 3179
2023
Q1 		$54.6K Sell
31,013
-28,653
-48% -$81.8K ﹤0.01% 2861
2022
Q4 		$187K Buy
59,666
+3,744
+7% +$14.5K ﹤0.01% 2634
2022
Q3 		$274K Buy
55,922
+3,475
+7% +$17.9K ﹤0.01% 2505
2022
Q2 		$218K Sell
52,447
-1,413
-3% -$6.11K ﹤0.01% 2596
2022
Q1 		$313K Sell
53,860
-231
-0.4% -$1.37K ﹤0.01% 2526
2021
Q4 		$405K Buy
54,091
+271
+0.5% +$2.35K ﹤0.01% 2477
2021
Q3 		$485K Buy
53,820
+23,912
+80% +$236K ﹤0.01% 2415
2021
Q2 		$357K Sell
29,908
-48
-0.2% -$543 ﹤0.01% 2405
2021
Q1 		$376K Buy
29,956
+2,684
+10% +$36.2K ﹤0.01% 2345
2020
Q4 		$426K Sell
27,272
-169
-0.6% -$1.98K ﹤0.01% 2291
2020
Q3 		$260K Sell
27,441
-4,867
-15% -$52.6K ﹤0.01% 2316
2020
Q2 		$290K Buy
32,308
+1,442
+5% +$13.4K ﹤0.01% 2281
2020
Q1 		$197K Sell
30,866
-5,119
-14% -$38K ﹤0.01% 2283
2019
Q4 		$301K Buy
35,985
+3,330
+10% +$30.6K ﹤0.01% 2314
2019
Q3 		$295K Buy
32,655
+9,230
+39% +$104K ﹤0.01% 2273
2019
Q2 		$252K Buy
23,425
+2,980
+15% +$31.7K ﹤0.01% 2289
2019
Q1 		$195K Buy
20,445
+2,379
+13% +$24.3K ﹤0.01% 2337
2018
Q4 		$208K Buy
18,066
+1,534
+9% +$19.1K ﹤0.01% 2294
2018
Q3 		$280K Hold
16,532
– – ﹤0.01% 2259
2018
Q2 		$235K Buy
16,532
+1,049
+7% +$17.4K ﹤0.01% 2268
2018
Q1 		$294K Sell
15,483
-5,875
-28% -$126K ﹤0.01% 2230
2017
Q4 		$354K Sell
21,358
-319
-1% -$4.75K ﹤0.01% 2171
2017
Q3 		$321K Buy
21,677
+2,903
+15% +$32.1K ﹤0.01% 2198
2017
Q2 		$167K Hold
18,774
– – ﹤0.01% 2371
2017
Q1 		$93K Hold
18,774
– – ﹤0.01% 2585
2016
Q4 		$57K Buy
18,774
+5,507
+42% +$20.1K ﹤0.01% 2850
2016
Q3 		$61K Hold
13,267
– – ﹤0.01% 2428
2016
Q2 		$76K Hold
13,267
– – ﹤0.01% 2249
2016
Q1 		$78K Buy
13,267
+2,848
+27% +$17.1K ﹤0.01% 2203
2015
Q4 		$96K Hold
10,419
– – ﹤0.01% 2100
2015
Q3 		$56K Hold
10,419
– – ﹤0.01% 2388
2015
Q2 		$111K Hold
10,419
– – ﹤0.01% 2036
2015
Q1 		$166K Hold
10,419
– – ﹤0.01% 1763
2014
Q4 		$160K Hold
10,419
– – ﹤0.01% 1700
2014
Q3 		$115K Buy
+10,419
New +$136K ﹤0.01% 1809

Other funds holding SGMO

WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Legal & General Group's SGMO Position: Q2 2024 in Review

Legal & General Group sold out of SANGAMO THERAPEUTICS INC (SGMO) in Q2 2024, closing a stake of 13,096 shares — an estimated $8.76K sold.

Legal & General Group first reported a position in SGMO in Q3 2014 and held it in 39 quarters. The position peaked at $485K in Q3 2021. 129 funds tracked by Wall St. Rank hold SGMO as of Q2 2024.

  • Legal & General Group reported no remaining SANGAMO THERAPEUTICS INC position as of Q2 2024 after selling out during the quarter.
  • Legal & General Group sold 13,096 SANGAMO THERAPEUTICS INC shares in Q2 2024, an estimated $8.76K.
  • Legal & General Group first reported a position in SANGAMO THERAPEUTICS INC in Q3 2014 and held it in 39 quarters.
  • Legal & General Group's SANGAMO THERAPEUTICS INC position peaked at $485K in Q3 2021.
  • 129 funds tracked by Wall St. Rank held SANGAMO THERAPEUTICS INC as of Q2 2024.

Based on Legal & General Group's 13F filing for Q2 2024, filed 14 Aug 2024.